Patient-Reported Outcomes (Pros) From A Phase 2 Trial Of Telisotuzumab Vedotin (Teliso-V) In C-Met-Overexpressing, Egfr Wild Type, Non-Squamous Non-Small Cell Lung Cancer (C-Met Oe, Egfr Wt, Nsq Nsclc)
Telisotuzumab Vedotin
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Patient-Reported Outcomes (Pros) From A Phase 2 Trial Of Telisotuzumab Vedotin (Teliso-V) In C-Met-Overexpressing, Egfr Wild Type, Non-Squamous Non-Small Cell Lung Cancer (C-Met Oe, Egfr Wt, Nsq Nsclc) ### Output: Telisotuzumab Vedotin